Condizione: As New. Unread book in perfect condition.
Lingua: Inglese
Editore: National Academies Press, US, 2017
ISBN 10: 0309455138 ISBN 13: 9780309455138
Da: Rarewaves.com USA, London, LONDO, Regno Unito
EUR 58,47
Quantità: 1 disponibili
Aggiungi al carrelloPaperback. Condizione: New. Compared with other disease areas, central nervous system (CNS) disorders have had the highest failure rate for new compounds in advanced clinical trials. Most CNS drugs fail because of efficacy, and the core issue underlying these problems is a poor understanding of disease biology. Concern about the poor productivity in neuroscience drug development has gained intensity over the past decade, amplified by a retraction in investment from the pharmaceutical industry. This retreat by industry has been fueled by the high failure rate of compounds in advanced clinical trials for nervous system disorders. In response to the de-emphasis of CNS disorders in therapeutic development relative to other disease areas such as cancer, metabolism, and autoimmunity, the National Academies of Sciences, Engineering, and Medicine initiated a series of workshops in 2012 to address the challenges that have slowed drug development for nervous system disorders. Motivated by the notion that advances in genetics and other new technologies are beginning to bring forth new molecular targets and identify new biomarkers, the Academies hosted the third workshop in this series in September 2016.Participants discussed opportunities to accelerate early stages of drug development for nervous system disorders in the absence of animal models that reflect disease and predict efficacy. This publication summarizes the presentations and discussions from the workshop.
Condizione: New.
Da: Ria Christie Collections, Uxbridge, Regno Unito
EUR 47,23
Quantità: 1 disponibili
Aggiungi al carrelloCondizione: New. In.
Da: Revaluation Books, Exeter, Regno Unito
EUR 50,74
Quantità: 1 disponibili
Aggiungi al carrelloPaperback. Condizione: Brand New. 94 pages. 13.74x8.94x0.24 inches. In Stock.
Da: GreatBookPricesUK, Woodford Green, Regno Unito
EUR 47,18
Quantità: 1 disponibili
Aggiungi al carrelloCondizione: New.
Da: GreatBookPricesUK, Woodford Green, Regno Unito
EUR 47,74
Quantità: 1 disponibili
Aggiungi al carrelloCondizione: As New. Unread book in perfect condition.
Da: THE SAINT BOOKSTORE, Southport, Regno Unito
EUR 58,70
Quantità: 1 disponibili
Aggiungi al carrelloPaperback / softback. Condizione: New. New copy - Usually dispatched within 3 working days.
EUR 67,86
Quantità: 1 disponibili
Aggiungi al carrelloCondizione: New.
Condizione: New.
Da: moluna, Greven, Germania
EUR 49,80
Quantità: 1 disponibili
Aggiungi al carrelloCondizione: New.
Lingua: Inglese
Editore: National Academies Press Jun 2017, 2017
ISBN 10: 0309455138 ISBN 13: 9780309455138
Da: AHA-BUCH GmbH, Einbeck, Germania
EUR 53,13
Quantità: 1 disponibili
Aggiungi al carrelloTaschenbuch. Condizione: Neu. Neuware - 'A report of the National Academies of Sciences, Engineering, Medicine.'.
Lingua: Inglese
Editore: National Academies Press, US, 2017
ISBN 10: 0309455138 ISBN 13: 9780309455138
Da: Rarewaves.com UK, London, Regno Unito
EUR 47,17
Quantità: 1 disponibili
Aggiungi al carrelloPaperback. Condizione: New. Compared with other disease areas, central nervous system (CNS) disorders have had the highest failure rate for new compounds in advanced clinical trials. Most CNS drugs fail because of efficacy, and the core issue underlying these problems is a poor understanding of disease biology. Concern about the poor productivity in neuroscience drug development has gained intensity over the past decade, amplified by a retraction in investment from the pharmaceutical industry. This retreat by industry has been fueled by the high failure rate of compounds in advanced clinical trials for nervous system disorders. In response to the de-emphasis of CNS disorders in therapeutic development relative to other disease areas such as cancer, metabolism, and autoimmunity, the National Academies of Sciences, Engineering, and Medicine initiated a series of workshops in 2012 to address the challenges that have slowed drug development for nervous system disorders. Motivated by the notion that advances in genetics and other new technologies are beginning to bring forth new molecular targets and identify new biomarkers, the Academies hosted the third workshop in this series in September 2016.Participants discussed opportunities to accelerate early stages of drug development for nervous system disorders in the absence of animal models that reflect disease and predict efficacy. This publication summarizes the presentations and discussions from the workshop.
Da: preigu, Osnabrück, Germania
EUR 56,20
Quantità: 1 disponibili
Aggiungi al carrelloTaschenbuch. Condizione: Neu. Therapeutic Development in the Absence of Predictive Animal Models of Nervous System Disorders | Proceedings of a Workshop | Board On Health Sciences Policy (u. a.) | Taschenbuch | Kartoniert / Broschiert | Englisch | 2017 | National Academies Press | EAN 9780309455138 | Verantwortliche Person für die EU: Libri GmbH, Europaallee 1, 36244 Bad Hersfeld, gpsr[at]libri[dot]de | Anbieter: preigu.